{
  "id": 7281597,
  "title": "Akeso presents positive HARMONi 2 trial survival data at WCLC",
  "url": "https://urgent.news/2026/09/14/akeso-presents-positive-harmoni-2-trial-survival-data-at-wclc",
  "topic": "business",
  "section": "Business",
  "published": "2026-09-14T08:44:44.000Z",
  "source": {
    "name": "Vietnam Investment Review",
    "slug": "vietnam-investment-review",
    "url": "https://vir.com.vn/akeso-presents-positive-harmoni-2-trial-survival-data-at-wclc-160707.html"
  },
  "original_language": "en",
  "account": "On September 13, 2026, Akeso, Inc. presented positive overall survival (OS) results from the HARMONi-2 study at the World Conference on Lung Cancer (WCLC). The Phase III, double-blind, multicenter, registrational study aimed to evaluate ivonescimab, a next-generation immuno-oncology therapy, against pembrolizumab as first-line treatment for PD-L1-positive advanced non-small cell lung cancer (NSCLC). The study demonstrated significant benefits of ivonescimab in prolonging OS compared to pembrolizumab, particularly in the PD-L1-high population and squamous NSCLC patients.",
  "summary": "Akeso presented positive overall survival results from its Phase III HARMONi 2 trial comparing ivonescimab to pembrolizumab in non small cell lung cancer patients at the World Conference on Lung Cancer",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}